MVM Capital has raised its fourth and largest funding round. It now has an additional €204M to invest in healthcare in the US and Europe.

mvm_capital_vc_healthcare_biotechWith offices in Boston and London, MVM Capital is an important VC in the healthcare sector – from biotechnology to medical devices.

Its biggest success story is perhaps Heptares, a UK Biotech researching applications of  G protein-coupled receptors (GPCRs) that was acquired by Sosei (Japan) – and went on to make billion euro deals with Pfizer and Allergan.

ADVERTISEMENT

MVM has now closed its fourth healthcare fund (MVM IV), raising a total of €204M ($233M). This is a record for MVM, which has so far raised over €600M in its four funds.

mvm_capital_biotech_vc_exits

Some of exits (IPOs or acquisition) of MVM’s portfolio that are based in Europe. (Source: MVM Capital)

MVM intends to spend their new funds mainly in a medical companies from the US and Europe.

It will consider all stages of development, as well as a range of sectors – from new therapeutics to medical devices and healthcare bioinformatics. The estimated investment per company will be from around €13M ($15M) to €26M ($30M).

mvm_capital_vc_pulmagen_xention_vantia

MVM’s portfolio companies based in Europe. (Source: MVM Capital)

A fair share of the current MVM’s portfolio is based in Europe, with companies like Wilson Therapeutics (Sweden), which is tackling a rare genetic disorder, as well as UK Biotechs Pulmagen Therapeutics and Xention.

These good results are in line with other record fundraisings, such as the €416M cancer fund by UBS and €180M by Forbion, and the overall health of VC financing in Biotech.


Previous post

This UK Company told us how they Optimise Drug Development and turn a Profit

Next post

Today is World Lupus Day! Meet the people who are fighting this Rare disease

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.